A10BX02 - Repaglinide |
Propably not porphyrinogenic |
PNP |
Rationale
Repaglinide does not induce or inhibit CYP3A4.
Risk for gastrointestinal adverse events in the form of abdominal pain and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Carbamoylmethyl benzoic acid derivative
Therapeutic characteristics
Repaglinide is indicated for the treatment of diabetes type 2 as monotherapy or in combination with metformin.
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are abdominal pain and diarrhoea.
Hepatic exposure
Probably not significant
Metabolism and pharmakokinetics
Repaglinide is metabolized mainly by CYP2C8 and to a smaller degree by CYP3A4 (SPC).
Repaglinide was co-administrated with theophylline, a CYP3A4 substrate, and did not induce or inhibit theophylline (Hatorp 2000).
References
- Scientific articles
- Hatorp V, Thomsen MS. Drug interaction studies with repaglinide: repaglinide on digoxin or theophylline pharmacokinetics and cimetidine on repaglinide pharmacokinetics. J Clin Pharmacol. 2000 Feb;40(2):184-92. PMID 10664925. #1129
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). repaglinid. #1130
Similar drugs
© NAPOS 2024